ID

22436

Description

Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00678964

Link

https://clinicaltrials.gov/show/NCT00678964

Keywords

  1. 6/4/17 6/4/17 -
Uploaded on

June 4, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small Cell Lung Cancer NCT00678964

Eligibility Non-Small Cell Lung Cancer NCT00678964

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytological proven nsclc, stage lll b (with pleural effusion) or stage lv.
Description

nsclc, tumor stage

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C1300072
tumor is locally advanced and not suitable for surgery and radiotherapy is not indicated.
Description

nsclc, locally advanced, not suitable for surgery and radiotherapy is not indicated

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0677984
UMLS CUI [1,3]
C0920424
UMLS CUI [1,4]
C1522449
neither cytostatic nor immunological pre-treatment
Description

prior chemotherapy, prior immunotherapy

Data type

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2]
C1514461
age >70 years
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
at least one measurable lesion (recist criteria) that was not previously irradiated
Description

measurable lesion, not previously irradiated

Data type

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C1513040
UMLS CUI [1,3]
C0279134
ecog performance status 0-1
Description

ecog

Data type

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy > 3 month
Description

life expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
adequate bone marrow function: anc > 1.5 x 109/l, platelets > 100 x 109/l
Description

anc, platelets

Data type

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0032181
adequate liver function: total bilirubin < 1.5 x uln, got/gpt< 3 x uln (existent liver metastases < 5 x uln)
Description

bilirubin, got, gpt

Data type

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0201836
adequate renal function:creatinine clearance > 45 ml/min (calculated according to cockroft-gault)
Description

creatinine clearance

Data type

boolean

Alias
UMLS CUI [1]
C0373595
fertile men must agree to use an effective method of birth control while participating in this study
Description

gender, fertility, contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0015895
UMLS CUI [1,3]
C0700589
signed written informed consent
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
uncontrolled metastasis in the cns
Description

cns metastasis, uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0205318
acute, heavy uncontrolled infection
Description

infection, uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0275518
UMLS CUI [1,2]
C0205318
any other serious concomitant disease or medical condition, which could interfere with participating in this study
Description

severe comorbidity

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
severe hypersensitivity to erlotinib or any other component
Description

hypersensitivity erlotinib

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1135135
hypersensitivity to carboplatin and/or other platinum compounds
Description

hypersensitivity carboplatin and/or other platinum compounds

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0079083
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C3536919
hypersensitivity to vinorelbin or other vinca-alkaloids
Description

hypersensitivity to vinorelbin or other vinca-alkaloids

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0078257
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0042672
patients with a history of other active malignancy in the past 5 years (with the exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma that was surgically treated successfully) are excluded.
Description

history of malignancy, with exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C2735088
UMLS CUI [2]
C0851140
UMLS CUI [3]
C3281209
UMLS CUI [4,1]
C0600139
UMLS CUI [4,2]
C0277565
participation in another clinical trial with any investigational drug at the same time or within 30 days prior to registration
Description

study subject participation status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
psychological, familial, social or geographical situations limiting the compliance with the study requirements
Description

compliance behaviour

Data type

boolean

Alias
UMLS CUI [1]
C1321605

Similar models

Eligibility Non-Small Cell Lung Cancer NCT00678964

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
nsclc, tumor stage
Item
histologically or cytological proven nsclc, stage lll b (with pleural effusion) or stage lv.
boolean
C0007131 (UMLS CUI [1,1])
C1300072 (UMLS CUI [1,2])
nsclc, locally advanced, not suitable for surgery and radiotherapy is not indicated
Item
tumor is locally advanced and not suitable for surgery and radiotherapy is not indicated.
boolean
C0007131 (UMLS CUI [1,1])
C0677984 (UMLS CUI [1,2])
C0920424 (UMLS CUI [1,3])
C1522449 (UMLS CUI [1,4])
prior chemotherapy, prior immunotherapy
Item
neither cytostatic nor immunological pre-treatment
boolean
C1514457 (UMLS CUI [1])
C1514461 (UMLS CUI [2])
age
Item
age >70 years
boolean
C0001779 (UMLS CUI [1])
measurable lesion, not previously irradiated
Item
at least one measurable lesion (recist criteria) that was not previously irradiated
boolean
C0221198 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C0279134 (UMLS CUI [1,3])
ecog
Item
ecog performance status 0-1
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy > 3 month
boolean
C0023671 (UMLS CUI [1])
anc, platelets
Item
adequate bone marrow function: anc > 1.5 x 109/l, platelets > 100 x 109/l
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
bilirubin, got, gpt
Item
adequate liver function: total bilirubin < 1.5 x uln, got/gpt< 3 x uln (existent liver metastases < 5 x uln)
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
creatinine clearance
Item
adequate renal function:creatinine clearance > 45 ml/min (calculated according to cockroft-gault)
boolean
C0373595 (UMLS CUI [1])
gender, fertility, contraceptive methods
Item
fertile men must agree to use an effective method of birth control while participating in this study
boolean
C0079399 (UMLS CUI [1,1])
C0015895 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
informed consent
Item
signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
cns metastasis, uncontrolled
Item
uncontrolled metastasis in the cns
boolean
C0686377 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
infection, uncontrolled
Item
acute, heavy uncontrolled infection
boolean
C0275518 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
severe comorbidity
Item
any other serious concomitant disease or medical condition, which could interfere with participating in this study
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
hypersensitivity erlotinib
Item
severe hypersensitivity to erlotinib or any other component
boolean
C0020517 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
hypersensitivity carboplatin and/or other platinum compounds
Item
hypersensitivity to carboplatin and/or other platinum compounds
boolean
C0020517 (UMLS CUI [1,1])
C0079083 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C3536919 (UMLS CUI [2,2])
hypersensitivity to vinorelbin or other vinca-alkaloids
Item
hypersensitivity to vinorelbin or other vinca-alkaloids
boolean
C0020517 (UMLS CUI [1,1])
C0078257 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0042672 (UMLS CUI [2,2])
history of malignancy, with exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma
Item
patients with a history of other active malignancy in the past 5 years (with the exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma that was surgically treated successfully) are excluded.
boolean
C2735088 (UMLS CUI [1])
C0851140 (UMLS CUI [2])
C3281209 (UMLS CUI [3])
C0600139 (UMLS CUI [4,1])
C0277565 (UMLS CUI [4,2])
study subject participation status
Item
participation in another clinical trial with any investigational drug at the same time or within 30 days prior to registration
boolean
C2348568 (UMLS CUI [1])
compliance behaviour
Item
psychological, familial, social or geographical situations limiting the compliance with the study requirements
boolean
C1321605 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial